The company is a subsidiary of Sichuan Colon Pharmaceutical Co., Ltd. invested and established in the Yining Industrial Park in Khorgos Economic Development Zone, Xinjiang in December 2010. The Khorgos Economic Development Zone is the core area of the Silk Road Economic Belt of the country's “Belt and Road” development strategy. It has built an erythromycin thiocyanate production line, two cephalosporin intermediate production lines, and a crude ursodeoxycholic acid production line. It is one of the largest domestic and global suppliers of antibiotic intermediates. The company is mainly engaged in the development and industrialization of biological fermentation technology and synthetic biological products. The company's main products include erythromycin thiocyanate, cephalosporin intermediates (7-ACA, 7-ADCA, D-7ACA), penicillin intermediates (6-APA, penicillin G potassium salt), crude ursodeoxycholic acid, coenzyme Q10 mycelium, etc. Corporate honors: In 2019, the Xinjiang Uygur Autonomous Region Department of Industry and Information Technology approved the “Tianchi Doctor Program” project; approved as the “Xinjiang Uyghur Autonomous Region High-tech Enterprise” in 2020; the “National Environmental Protection Antibiotic Bacterial Residue Harmless Treatment and Resource Utilization Engineering Technology Center” established by the company passed the inspection; in 2021, it was approved by the Autonomous Region Human Resources and Social Security Department to establish the Autonomous Region Postdoctoral Research Workstation, etc. It won the honorary title of “National Model Worker”.
No Data